Search

Your search keyword '"Xiong, H."' showing total 24 results
Start Over Author "Xiong, H." Journal annals of oncology
24 results on '"Xiong, H."'

1. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Author

Bang, Y.-J, Ruiz, E.Yañez, Van Cutsem, E., Lee, K.-W, Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H, Chung, H.-C, Evesque, L., Al-Batran, S.-E, Park, S.H., Lichinitser, M., Boku, N., Moehler, M.H., Hong, J., Xiong, H., Hallwachs, R., Conti, I., and Taieb, J.

Published
2018
Full Text
View/download PDF

2. 1411P A prospective, multicenter, real-world study of apatinib in the treatment of gastric cancer

Author

Xiong, J., primary, Yang, J., additional, Li, W., additional, Xiong, H., additional, Liu, G., additional, Wu, F., additional, Fan, N., additional, Zeng, X., additional, Huang, F., additional, Yang, L., additional, Tu, X., additional, Shi, C., additional, Yi, B., additional, Ye, J., additional, Li, P., additional, Tang, C., additional, Huang, J., additional, Hou, P., additional, Zang, W., additional, and Tan, S., additional

Published
2021
Full Text
View/download PDF

4. 138O Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

Author

van den Bent, M., primary, Lassman, A.B., additional, Gan, H.K., additional, Reardon, D.A., additional, Kumthekar, P., additional, Butowski, N., additional, Lwin, Z., additional, Mikkelsen, T., additional, Nabors, L.B., additional, Papadopoulos, K.P., additional, Penas-Prado, M., additional, Simes, J., additional, Wheeler, H., additional, Gomez, E., additional, Lee, H-J., additional, Roberts-Rapp, L., additional, Xiong, H., additional, Bain, E., additional, Holen, K., additional, and Merrell, R., additional

Published
2016
Full Text
View/download PDF

7. A phase 1 study of single agent veliparib in Japanese subjects with advanced solid tumors

Author

Matsumoto, K., primary, Tamura, K., additional, Yoshida, H., additional, Nishikawa, T., additional, Imai, Y., additional, Miyasaka, A.M., additional, Onoe, T., additional, Yamaguchi, S., additional, Shimizu, C., additional, Yonemori, K., additional, Shimoi, T., additional, Yunokawa, M., additional, Xiong, H., additional, Hashiba, H., additional, Kiriyama, T., additional, Leahy, T., additional, Shepherd, S., additional, and Fujiwara, K., additional

Published
2016
Full Text
View/download PDF

8. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

Author

Lassman, A.B., primary, van den Bent, M., additional, Gan, H.K., additional, Reardon, D.A., additional, Kumthekar, P., additional, Butowski, N., additional, Lwin, Z., additional, Mikkelsen, T., additional, Nabors, L.B., additional, Papadopoulos, K.P., additional, Penas-Prado, M., additional, Simes, J., additional, Wheeler, H., additional, Gomez, E., additional, Lee, H.-J., additional, Roberts-Rapp, L., additional, Xiong, H., additional, Bain, E., additional, Holen, K., additional, and Merrell, R., additional

Published
2016
Full Text
View/download PDF

11. A Phase 1 Study of Veliparib (Abt-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with Non-Small Cell Lung Cancer (Nsclc)

Author

Mizugaki, H., primary, Nokihara, H., additional, Yamamoto, N., additional, Fujiwara, Y., additional, Horinouchi, H., additional, Kanda, S., additional, Kitazono, S., additional, Yagishita, S., additional, Xiong, H., additional, Qian, J., additional, Shepherd, S., additional, Giranda, V.L., additional, and Tamura, T., additional

Published
2014
Full Text
View/download PDF

12. A Study of Abt-767 in Advanced Solid Tumors with Brca 1 and Brca 2 Mutations and High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Author

de Jonge, M.J.A., primary, van Herpen, C., additional, Gietema, J.A., additional, Shepherd, S., additional, Koornstra, R., additional, Jager, A., additional, De Hollander, M. n, additional, Dunbar, M., additional, Hetman, R., additional, Serpenti, C., additional, Xiong, H., additional, Zhu, M., additional, and Giranda, V.L., additional

Published
2014
Full Text
View/download PDF

13. A Phase 1 Study Evaluating Abt-414 with Concurrent Radiotherapy (Rt) and Temozolomide (Tmz) in Newly Diagnosed Glioblastoma (Gbm)

Author

Gan, H.K., primary, Fichtel, L., additional, Lassman, A., additional, Merrell, R., additional, van den Bent, M.J., additional, Kumthekar, P., additional, Scott, A., additional, Pedersen, M., additional, Gomez, E., additional, Fischer, J., additional, Ames, W., additional, Xiong, H., additional, Dudley, M., additional, Roberts-Rapp, L., additional, Ansell, P.J., additional, Holen, K., additional, and Reardon, D.A., additional

Published
2014
Full Text
View/download PDF

14. Interim Safety Results from Steam: a Randomized Phase 2 Trial of Sequential and Concurrent Folfoxiri–Bevacizumab (Bev) Vs Folfox–Bev for the First-Line (1L) Treatment (Tx) of Patients (Pts) with Metastatic Colorectal Cancer (Mcrc)

Author

Hurwitz, H., primary, Tan, B., additional, Reeves, J., additional, Xiong, H., additional, Lenz, H., additional, Hochster, H., additional, Laeufle, R., additional, Sommer, N., additional, Young, J., additional, Byrtek, M., additional, and Bendell, J., additional

Published
2014
Full Text
View/download PDF

17. Linifanib Plus Carboplatin/Paclitaxel in Japanese Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer

Author

Terashima, M., primary, Nakagawa, K., additional, Okabe, T., additional, Kaneda, H., additional, Yamamoto, N., additional, Nokihara, H., additional, Horinouchi, H., additional, Horai, T., additional, Nishio, M., additional, Ohyanagi, F., additional, Horiike, A., additional, McKee, M., additional, Carlson, D., additional, Xiong, H., additional, and Tamura, T., additional

Published
2012
Full Text
View/download PDF

22. LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort.

Author

Hu, X., Zhang, Q., Sun, T., Xiong, H., Li, W., Teng, Y., Lu, Y-S., Tseng, L-M., Yan, M., Li, H., Pang, D., Chen, S.C., Chen, W., Jiang, O., Wang, J., Wu, X., Fan, E., Jiang, L., Zeng, X., and Turner, N.

Subjects
*CLINICAL trials, *METASTATIC breast cancer, *FULVESTRANT, *AROMATASE inhibitors, *ARTIFICIAL intelligence
Published
2023
Full Text
View/download PDF

23. LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis.

Author

Lu, S., Cho, B.C., Lee, J-S., Lee, S-H., Danchaivijitr, P., Liu, B., Alip, A., Xiong, H., How, S.H., Chang, G-C., Yang, J.C-H., Yoshioka, H., Xia, K., Martinez, M., Bauml, J.M., Sethi, S., and Hayashi, H.

Subjects
*NON-small-cell lung carcinoma, *ASIANS, *OSIMERTINIB, *SUBGROUP analysis (Experimental design)
Published
2023
Full Text
View/download PDF

24. P1:03 ANALYSIS OF BIOMARKERS AND PK MODELING OF ABT-767 IN PATIENTS WITH BRCA1/BRCA2-MUTATED TUMORS OR HIGH GRADE SEROUS OVARIAN CANCER

Author

de Jonge, M., van Herpen, C., Gietema, J., Timms, K., Dunbar, M., Hetman, R., Serpenti, C., Xiong, H., Zhu, M., Mittapalli, R., Ansell, P., and Shepherd, S.

Abstract

Background: Malignancies with homologous repair deficiency (HRD) are more dependent on PARP for DNA repair than normal cells. This trial assessed safety and PK of the oral PARP-1 and -2 inhibitor, ABT-767. Here we present biomarker and PK modeling results in patients ( pts) with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer or solid tumors with germline (g) BRCA1 or BRCA2 mutation. Materials and methods: In this Phase I, single-agent, dose escalation study, pts received ABT-767 20mg QD to 500mg BID on days 1-28 on a 28-day cycle to assess safety and PK. Tumor BRCA1 and BRCA2 mutation screening and HRD score analyses were performed using a next generation sequencing assay. Dose, BRCA mutation, platinum sensitivity, baseline CA125 level (if relevant), and age were examined as potential predictive variables for efficacy and safety responses. Results: As of Nov 10, 2014, 93 pts were treated; 86% had a primary diagnosis of ovarian cancer. 45% had known gBRCA mutations. Cmax and AUC were dose-proportional from 20-500mg BID. By RECIST 1.1 and/or CA-125 criteria: 13 (14%) CR, 14 (15%) PR; median PFS 110 days. 78 pts submitted tissue for biomarker testing, and HRD status was determined for 63. 34 pts were HR-deficient; of these, 26 had deleterious BRCA mutations. Of 16 RECIST 1.1 and/or CA-125 responders tested, all were HR-deficient; 14/16 had deleterious BRCA mutations. 8 pts had high HRD without deleterious BRCA mutation (2 had CR at 400mg BID; OS > 330 and 368 days, respectively). HR-deficient pts had prolonged PFS (log rank p < 0.05). Logistical regression analyses revealed platinum sensitivity and BRCA status to be significant covariates affecting best tumor response and PFS. Pts with gBRCA mutations also experienced a higher rate of grade 3/4 anemia across dose groups. Conclusions: As reported previously, ABT-767 has an acceptable safety profile for Phase 2 studies and has single-agent activity in pts with BRCA mutations or high-grade serous ovarian cancer. BRCA mutations, HRD score and platinum sensitivity were associated with response, and gBRCA mutation carriers demonstrated a trend for increased grade 3/4 anemia that was manageable. Overall, these analyses identify pt populations who may be more sensitive to PARP inhibition by ABT-767. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results